Citation Tools

Download PDFPDF

256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699)

Download to a citation manager

Cite this article as:
Perez C, Wesolowski R, Wilky B, et al
256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699)